Related Experiment Video
Updated: Oct 16, 2026

Mouse Model of Alloimmune-induced Vascular Rejection and Transplant Arteriosclerosis
Published on: May 17, 2015
Effects of bradykinin on coronary blood flow and vasomotion in transplant patients
E Aptecar1, E Teiger, P Dupouy
1Fédération de Cardiologie et Institut National de la Santé et de la Recherche Médicale U400, Créteil, France. eaptecar@club-inernet.fr
Insights
Bradykinin preserves coronary vasodilation in heart transplant patients, even with rejection. Acetylcholine causes abnormal vasoconstriction, indicating preserved endothelial function post-transplant.
Area of Science:
- Cardiology
- Transplant Medicine
- Vascular Biology
Background:
- Coronary endothelial dysfunction is common early after heart transplantation.
- Acetylcholine has been used to identify this dysfunction.
- Bradykinin's effects on coronary vasomotion in transplant patients are unknown.
Purpose of the Study:
- To assess exogenous bradykinin's impact on coronary epicardial and microcirculatory tone in heart transplant recipients (HTXs).
- To compare bradykinin's effects with those of acetylcholine in HTXs.
Main Methods:
- Compared 16 HTXs (3.6 months post-transplant) with 7 controls.
- Measured coronary flow velocity using guide-wire Doppler.
- Assessed left coronary artery diameter and coronary blood flow (CBF) during bradykinin and acetylcholine infusions.
Main Results:
- Bradykinin caused dose-dependent vasodilation and increased CBF in both HTXs and controls.
- Acetylcholine induced vasodilation in controls but vasoconstriction in HTXs.
- Acute allograft rejection did not alter bradykinin response but reduced acetylcholine-induced CBF increase.
Conclusions:
- Coronary vasodilating effects of bradykinin are maintained early after heart transplantation.
- Despite abnormal acetylcholine response suggesting endothelial dysfunction, the endothelium remains functionally active in HTXs.
- Bradykinin serves as a reliable vasodilator in heart transplant recipients.
Objectives:
To evaluate the effects of exogenous bradykinin on coronary epicardial and microcirculatory tone in transplant patients (HTXs), and to compare them with the effects of acetylcholine.
Background:
Coronary endothelial dysfunction has been reported to occur early after heart transplantation, most notably when acetylcholine was the endothelium-function marker used. The effects of bradykinin on coronary vasomotion are unknown in HTXs.
Methods:
Sixteen HTXs were compared 3.6 +/- 1.7 months after transplantation to seven control subjects. Coronary flow velocity was measured using guide-wire Doppler. Diameters (D) of three segments of the left coronary artery and coronary blood flow (CBF) were assessed at baseline, after 3-min infusions of increasing bradykinin doses (50, 150 and 250 ng/min) then of increasing acetylcholine doses (estimated blood concentrations of 10(-8), 10(-7) and 10(-6) M).
Results:
Bradykinin induced similar dose-dependent increases in D and CBF in both groups: D was 11 +/- 12%, 19 +/- 14% and 22 +/- 16% (all p < 0.0001), and CBF was 50 +/- 40%, 130 +/- 68% and 186 +/- 77% (all p < 0.0001). Acetylcholine induced significant epicardial vasodilation in control subjects and vasoconstriction in HTX, as well as a marked increase in CBF in both groups. Acute allograft rejection, present in 8 of the 16 HTXs, did not modify responses to bradykinin, but was associated with a smaller CBF increase in response to acetylcholine (p < 0.05).
Conclusions:
The coronary vasodilating effects of bradykinin are preserved early after heart transplantation, even in the presence of acute allograft rejection. Although there is an abnormal vasoconstricting response to acetylcholine reflecting endothelium dysfunction, the endothelium remains a functionally active organ in heart transplant recipients.
Related Concept Videos
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Heart Failure Drugs: β-Blockers
Kidney Transplant I: Introduction
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Pathophysiology of Cardiac Performance
Antihypertensive Drugs: Action of β1 Blockers

